TABLE 1.
Comorbidities associated with COVID-19 related hospitalized cases and deaths.
| Conditions |
Countries |
|||||||||||||||
|
Italy |
France |
Netherlands |
Sweden |
Spain |
||||||||||||
| Hosp | Death | P value | Hosp | Death | P value | Hosp | Death | P value | Hosp | Death | P value | Hosp | Death | P value | ||
| N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | |||||||
| Heart Diseases | Cardiovascular diseases | 219 (21) | 1568 (77) | <0.0001 | 612 (19) | 118 (33) | <0.0001 | 2635 (48) | 874 (50) | 0.1468 | 389 (34) | 596 (54) | <0.0001 | 19565 (36) | 6650 (53) | <0.0001 |
| Hypertension | 511 (49) | 1410 (69) | <0.0001 | 202 (35*) | 11 (26*) | 0.231# | NA | NA | – | 426 (37) | NA | NA | NA | NA | – | |
| Diabetes | 177 (17) | 647 (32) | <0.0001 | 797 (25) | 112 (31) | 0.0134 | 1258 (23) | 413 (24) | 0.3906# | 279 (24) | 277 (25) | 0.5814# | 10239 (19) | 3458 (27) | <0.0001 | |
| Chronic lung diseases | 41 (4) | 460 (23) | <0.0001 | 515 (16) | 84 (23) | 0.0007 | 1342 (25) | 419 (24) | 0.4008# | 162 (14) | 191 (17) | 0.0492 | 6439 (12) | 2165 (17) | <0.0001 | |
| Kidney diseases | 31 (3) | 431 (21) | <0.0001 | 181 (6) | 35 (10) | 0.0033 | 414 (8) | 185 (11) | 0.0001 | 38 (3) | 187 (17) | <0.0001 | NA | NA | – | |
| Liver diseases | 31 (3) | 81 (4) | 0.1619# | 6 (1*) | 0 (0*) | - | 65 (1) | 15 (1) | 1 | 8 (1) | 13 (1) | 1 | NA | NA | – | |
| Immunodeficiency | NA | 5 (0.20) | – | 200 (6) | 32 (9) | 0.0264 | 84 (2) | 16 (1) | 0.0058 | 61 (5) | 59 (5) | 1 | NA | NA | – | |
| Neurological diseases | NA | 307 (15) | – | 102 (3) | 24 (7) | 0.0001 | 273 (5) | 216 (13) | <0.0001 | 12 (1) | NA | – | NA | NA | – | |
| Total comorbidity associated hospitalized cases/deaths | 1043 | 2041 | – | 3192 OR 578* | 360 OR 43* | - | 5462 | 1732 | – | 1141 | 1109 | – | 55039 | 12642 | – | |
The table represents country-wise COVID-19 patients with associated comorbidities in numbers (N) as well as percentage (%). All the percentage values are rounded up. One patient may belong to several other groups. For France, Italy, and Sweden the hospitalized patients’ data was available and considered for intensive care unit (ICU) patients only. While for Spain the hospitalized plus ICU patients and for Netherlands patients admitted in hospital was considered in the category of hospitalized patients. The count of patients with other than enlisted comorbidities presented in the original reports have not been included in the table but considered in the total. NA, Not available; Hosp., Hospitalized patients. (Timespan for country wise data: Italy- Hosp.-NA, death- 21/02/2020–23/04/2020; France- 16/03/2020–21/04/2020; ∗France comorbidities data collected from 04/04/2020 (578 cases including 43 deaths); Spain-31/01/2020–22/04/2020; Netherlands-27/02/2020–10/04/2020; Sweden- 13/04/2020–19/04/2020). Neurological disease = Neuromuscular + neurovascular diseases; Cardiovascular disease = Ischemic heart disease + Atrial fibrillation + Heart failure + Stroke (Italy); Chronic lung disease = respiratory disease (spain)/ pulmonary disease (France); Immunodeficiency = HIV (Italy), Neurological disease = Dementia (Italy). #p > 0.05-not significant; p < 0.05-significant calculated from t-Test two-tailed.